RxSight, Inc. $RXST Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its stake in RxSight, Inc. (NASDAQ:RXST) by 7.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 897,846 shares of the company’s stock after selling 74,693 shares during the quarter. Millennium Management LLC owned about 2.21% of RxSight worth $22,671,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of RxSight by 0.4% in the first quarter. Vanguard Group Inc. now owns 2,392,052 shares of the company’s stock valued at $60,399,000 after purchasing an additional 8,504 shares during the last quarter. Credit Agricole S A increased its stake in RxSight by 32.8% during the first quarter. Credit Agricole S A now owns 786,063 shares of the company’s stock worth $19,848,000 after acquiring an additional 194,032 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in RxSight by 885.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 719,818 shares of the company’s stock worth $18,176,000 after acquiring an additional 646,791 shares during the last quarter. Royal Bank of Canada increased its stake in RxSight by 3,094.6% during the fourth quarter. Royal Bank of Canada now owns 508,491 shares of the company’s stock worth $17,481,000 after acquiring an additional 492,574 shares during the last quarter. Finally, Northern Trust Corp increased its stake in RxSight by 8.7% during the first quarter. Northern Trust Corp now owns 438,425 shares of the company’s stock worth $11,070,000 after acquiring an additional 35,021 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analysts Set New Price Targets

RXST has been the subject of several recent analyst reports. Wall Street Zen cut RxSight from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Stifel Nicolaus cut their target price on RxSight from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Friday, August 8th. Oppenheimer cut RxSight from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 9th. Needham & Company LLC cut their target price on RxSight from $22.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Zacks Research raised RxSight from a “strong sell” rating to a “hold” rating in a research note on Monday, September 8th. One analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $10.00.

RxSight Trading Down 1.2%

Shares of NASDAQ RXST opened at $9.31 on Friday. RxSight, Inc. has a twelve month low of $6.32 and a twelve month high of $57.53. The stock has a fifty day simple moving average of $8.41 and a 200-day simple moving average of $14.50. The stock has a market capitalization of $380.97 million, a PE ratio of -11.64 and a beta of 1.18.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.04). The firm had revenue of $33.64 million during the quarter, compared to analyst estimates of $39.78 million. RxSight had a negative net margin of 21.93% and a negative return on equity of 11.56%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. On average, equities analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.